TGTX تصريحات هيئة الأوراق المالية والبورصات - TG Therapeutics, Inc.- التقرير السنوي، بيان التوكيل، نشرة الإصدار

الإحصائيات الأساسية

LEI	529900X21UKABN9NJ529
CIK	1001316

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to TG Therapeutics, Inc.

SEC Filings (Chronological Order)

توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.

August 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG T
August 8, 2025	EX-FILING FEES	Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 TG THERAPEUTICS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.001 Other 5,000,000 $ 28.72 $ 143,600,000.00 0.0001531 $ 21,985.16 Total Offering Am
August 8, 2025	EX-10.1	Amendment No. 2 to the TG Therapeutics, Inc. 2022 Incentive Plan, dated April 11, 2025. Exhibit 10.1 AMENDMENT NO. 2 TO THE TG THERAPEUTICS, INC. 2022 INCENTIVE PLAN THIS AMENDMENT NO. 2 (the “Amendment”) to the TG Therapeutics, Inc. 2022 Incentive Plan (the “Plan”) is adopted as of April 11, 2025, subject to and effective upon the approval of the shareholders at the 2025 annual meeting. W I T N E S S E T H: WHEREAS, TG Therapeutics, Inc. (the “Company”) maintains the Plan, and the P
August 8, 2025	EX-FILING FEES	Filing Fee Table† Calculation of Filing Fee Tables S-3 TG THERAPEUTICS, INC. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initi
August 8, 2025	S-8	As filed with the Securities and Exchange Commission on August 8, 2025 As filed with the Securities and Exchange Commission on August 8, 2025 File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TG THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-3898269 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer I
August 8, 2025	EX-4.3	Form of Indenture† Exhibit 4.3 TG THERAPEUTICS, INC. FORM OF INDENTURE Dated as of [ ], 20[ ] DEBT SECURITIES [ ] Trustee CROSS REFERENCE SHEET Cross-reference sheet of provisions of the Trust Indenture Act of 1939 and this indenture* Trust Indenture Act Section Indenture Section §310 (a) 11.04(a), 16.02 (b) 11.01(f), 11.04(b), 11.05(1), 16.02 (b)(1) 11.04(b), 16.02 §311 11.01(f), 16.02 §312 14.02(d), 16.02 (b) 11.1
August 8, 2025	S-3ASR	As filed with the Securities and Exchange Commission on August 8, 2025 Table of Contents As filed with the Securities and Exchange Commission on August 8, 2025 Registration No.
August 4, 2025	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million Raises full year 2025 BRIUMVI U.S. net revenue target to approximately $570 - $575 million Conference call to be held today, Monday, August 4, 2025, at 8:30 AM ET New York, NY, (Augus
August 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2025 TG Therapeutics, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2025 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Employ
June 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2025 TG Therapeutics, In UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2025 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Employe
May 9, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG
May 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2025 TG Therapeutics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2025 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Employer
May 5, 2025	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to approximately $560 million Conference call to be held today, Monday, May 5, 2025, at
April 30, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted
April 30, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(
April 18, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitte
March 3, 2025	EX-21.1	Subsidiaries of TG Therapeutics, Inc. Exhibit 21.1 Subsidiaries of TG Therapeutics, Inc. Ariston Pharmaceuticals, Inc. TG Biologics, Inc. TG Therapeutics AUS Pty Ltd TG Cell Therapy, Inc.
March 3, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. ☐ TRANSITION REPORT PURSUANT TO SECT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 1-32639 TG THER
March 3, 2025	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Statements of Operations Information (in thousands, except share and per share amounts; unaudited): Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results Fourth quarter and full year 2024 BRIUMVI U.S. net revenue of $103.6 million and $310 million, respectively Target guidance of approximately $540 million in total global revenue for 2025 Conference call to be held today, March 3, 2025, at 8:30 AM ET New York, NY, (March 3, 2025) –
March 3, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2025 TG Therapeutics, In UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2025 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Employe
January 14, 2025	EX-99.1	TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones Exhibit 99.1 TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectively Full Year 2025 target total global revenue of approximately $540 million, including BRIUMVI U.S. net product revenue of approximatel
January 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 14, 2025 TG Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 14, 2025 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Empl
November 14, 2024	SC 13G/A	TGTX / TG Therapeutics, Inc. / Darwin Global Management, Ltd. - TG THERAPEUTICS, INC Passive Investment SC 13G/A 1 p24-3061sc13ga.htm TG THERAPEUTICS, INC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* TG Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 88322Q108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Chec
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639
November 7, 2024	EX-10.1	Master Services Agreement between FUJIFILM DIOSYNTH BIOTECHNOLOGIES NORTH CAROLINA, INC, FUJIFILM DIOSYNTH BIOTECHNOLOGIES DENMARK APS and TG Therapeutics, Inc., effective October 8, 2024. Exhibit 10.1 (1) FUJIFILM DIOSYNTH BIOTECHNOLOGIES NORTH CAROLINA, INC.; (2) FUJIFILM DIOSYNTH BIOTECHNOLOGIES DENMARK APS AND (3) TG THERAPEUTICS, INC. CONTENTS 1. Definitions and Interpretation 1 2. Appointment of Fujifilm AND SCOPE OF SERVICES 11 3. Term 12 4. Performance of Program 12 5. Quality AND REGULATORY MATTERS 13 6. Conforming batches AND NON-CONFORMING BATCHES 15 7. Delivery, TITLE AN
November 4, 2024	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million Conference call to be held today, November 4, 2024, at 8:30 AM ET New York, NY, (November 4, 2024) – TG Therapeutics, Inc.
November 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2024 TG Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2024 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Empl
August 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG T
August 9, 2024	EX-10.2	Financing Agreement between TG Therapeutics, Inc., certain subsidiaries of TG Therapeutics, Inc., various lenders from time to time party thereto, and Blue Owl Capital Corporation, dated August 2, 2024. Exhibit 10.2 Redacted Version CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”. FINANCING AGREEMENT dated as of August 2, 2024 among TG THERAPEUTICS, INC., as Borrower, CERTAIN SUBSIDIARIES OF BORROWER, as Guarantors, VARIOUS LEN
August 9, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. ☐ TRANSITION REP -12-31FY2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number
August 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2024 TG Therapeutics, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2024 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Employ
August 6, 2024	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance Second quarter 2024 U.S. BRIUMVI net revenue of $72.6 million Raising full year 2024 U.S. BRIUMVI net revenue target to approximately $290 - $300 million Cash flow positive for second quarter 2024 Establishes $250 million credit facility to repay existing deb
June 17, 2024	EX-10.1	Amendment to the TG Therapeutics, Inc. 2022 Incentive Plan. Exhibit 10.1 AMENDMENT TO THE TG THERAPEUTICS, INC. 2022 INCENTIVE PLAN THIS AMENDMENT (the “Amendment”) to the TG Therapeutics, Inc. 2022 Incentive Plan (the “Plan”) is adopted as of June 14, 2024, subject to and effective upon the approval of the shareholders at the 2024 annual meeting. W I T N E S S E T H: WHEREAS, TG Therapeutics, Inc. (the “Company”) maintains the Plan, and the Plan is curren
June 17, 2024	EX-3.1	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of TG Therapeutics, Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TG THERAPEUTICS, INC. TG Therapeutics, Inc., a corporation organized and existing under and by virtue of the Delaware General Corporation Law (the “Corporation”), does hereby certify: FIRST: That on April 17, 2024, the Board of Directors of the Corporation adopted resolutions setting forth a proposed amend
June 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2024 TG Therapeutics, In -12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2024 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS
June 13, 2024	PX14A6G	SECURITIES & EXCHANGE COMMISSION WASHINGTON, D.C. 20549 NOTICE OF EXEMPT SOLICITATION (VOLUNTARY SUBMISSION) SECURITIES & EXCHANGE COMMISSION WASHINGTON, D.C. 20549 NOTICE OF EXEMPT SOLICITATION (VOLUNTARY SUBMISSION) Name of Registrant: TG Therapeutics, Inc. Name of persons relying on exemption: Los Angeles County Employees Retirement Association (LACERA) Address of persons relying on exemption: 300 N. Lake Avenue, Pasadena, CA 91101 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgat
June 10, 2024	PX14A6G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION 1. Name of the Registrant: TG Therapeutics, Inc. 2. Name of person relying on exemption: CalSTRS Investments 3. Address of person relying on exemption: 100 Waterfront Place, MS 04, West Sacramento, CA 95605-2807 4. Written Materials: Attach written material required to be submitted pursuant to Rul
May 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG
May 1, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2024 TG Therapeutics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2024 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Employer
May 1, 2024	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Statements of Operations Information (in thousands, except share and per share amounts; unaudited): Exhibit 99.1 TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results First quarter 2024 BRIUMVI U.S. net revenue of $50.5 million, representing >25% quarter over quarter growth Total revenue for Q1 2024 of $63.5 million, including a $12.5 million milestone payment for BRIUMVI launch in first EU country New BRIUMVI prescriptions to the TG hub of over 1,250 for Q1 2
April 29, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)
April 29, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitte
April 18, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitte
February 29, 2024	EX-19.1	1 Exhibit 19.1 Insider Trading Policy I. PURPOSE TG Therapeutics, Inc. (the “Company”) has adopted this Insider Trading Policy (this “Policy”) to help its Employees, Consultants, Officers, and Directors, comply with insider trading laws and to prevent the appearance of improper insider trading. Insider trading laws prohibit a person from: ● using material nonpublic information to make decisions to p
February 29, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. ☐ TRANSITION REPORT PURSUANT TO SECT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 1-32639 TG THER
February 29, 2024	EX-97.1	TG Therapeutics, Inc. Incentive Compensation Recovery Policy Exhibit 97.1 TG Therapeutics, Inc. Incentive Compensation Recovery Policy 1.0 General. 1.1 TG Therapeutics, Inc. (the “Company”) has adopted this Policy in accordance with the applicable listing standards of Nasdaq and Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which require listed companies to adopt and comply with a compensation recovery policy. To the
February 29, 2024	EX-21.1	Subsidiaries of TG Therapeutics, Inc. Exhibit 21.1 Subsidiaries of TG Therapeutics, Inc. Ariston Pharmaceuticals, Inc. TG Biologics, Inc. TG Therapeutics AUS Pty Ltd TG Cell Therapy, Inc.
February 29, 2024	EX-10.38	not material and is the type that the registrant treats as private or confidential. LICENSE AGREEMENT by and among TG THERAPEUTICS, INC., TG CELL THERAPY, INC. PRECISION BIOSCIENCES, INC. LICENSE AGREEMENT Exhibit 10.38 Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. LICENSE AGREEMENT by and among TG THERAPEUTICS, INC., TG CELL THERAPY, INC. and PRECISION BIOSCIENCES, INC. LICENSE AGREEMENT This License Agreement (“Agreement”) is entered into as of January 7, 2024 (the “Effe
February 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2024 TG Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2024 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Emp
February 28, 2024	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results Fourth quarter and full year 2023 BRIUMVI U.S. net revenue of approximately $40 million and $89 million, respectively Conference call to be held today, February 28, 2024, at 8:30 AM ET New York, NY, (February 28, 2024) – TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therap
February 14, 2024	SC 13G/A	TGTX / TG Therapeutics, Inc. / Darwin Global Management, Ltd. - TG THERAPEUTICS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TG Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 88322Q108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant t
February 13, 2024	SC 13G/A	TGTX / TG Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: TG Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 88322Q108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒
January 10, 2024	EX-99.1	TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones Exhibit 99.1 TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones Preliminary U.S. BRIUMVI fourth quarter and full year 2023 net product revenue of approximately $40 million and $89 million, respectively Preliminary year-end 2023 cash position of approximately $215 million NEW YORK, January 10, 2024 - TG Therapeutics, Inc. (NASDAQ: TGTX
January 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2024 TG Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2024 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Emplo
November 6, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639
November 1, 2023	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results Third quarter 2023 total net revenue of $165.8 million, including quarterly BRIUMVI® net sales of $25.1 million in the United States, and license revenue of $140.0 million from the upfront payment received from Neuraxpharm Approximately 2,200 BRIUMVI prescriptions since launch from 500+ healthcar
November 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2023 TG Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2023 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Empl
August 4, 2023	EX-10.1	Commercialization Agreement by and between TG Therapeutics, Inc. and Neuraxpharm Pharmaceuticals, S.L., dated as of July 28, 2023. + Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***].” COMMERCIALIZATION AGREEMENT This COMMERCIALIZATION AGREEMENT (this “Agreement”) is entered into as of July 28, 2023 (the “Effective Date”) by and between TG Therapeut
August 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG T
August 1, 2023	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results Second quarter 2023 BRIUMVI® net sales of $16 million in the United States, representing 100% quarter over quarter growth; total net revenue of approximately $24 million since launch Over 1,200 BRIUMVI prescriptions since launch from 340+ healthcare providers at 225+ centers across the U.S. Payo
August 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 28, 2023 TG Therapeutics, In UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 28, 2023 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Employe
June 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2023 TG Therapeutics, In UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2023 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Employe
May 8, 2023	EX-10.6	Warrant Agreement, dated March 31, 2023, by and between TG Therapeutics, Inc. and Hercules Capital Inc. Exhibit 10.6 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUN
May 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG
May 8, 2023	EX-10.2	Amended and Restated Warrant Agreement, dated March 31, 2023, by and between TG Therapeutics, Inc. and Hercules Capital Inc. Exhibit 10.2 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUN
May 8, 2023	EX-10.7	Warrant Agreement, dated March 31, 2023, by and between TG Therapeutics, Inc. and Hercules Private Credit Fund 1 L.P. Exhibit 10.7 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUN
May 8, 2023	EX-10.5	Amended and Restated Warrant Agreement, dated March 31, 2023, by and between TG Therapeutics, Inc. and Hercules Private Global Venture Growth Fund I L.P. Exhibit 10.5 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUN
May 8, 2023	EX-10.8	Warrant Agreement, dated March 31, 2023, by and between TG Therapeutics, Inc. and Hercules Private Global Venture Growth Fund I L.P. Exhibit 10.8 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUN
May 8, 2023	EX-10.1	First Amendment to Amended and Restated Loan and Security Agreement, dated March 31, 2023, by and among TG Therapeutics, Inc., TG Biologics, Inc. and Hercules Capital, Inc. Exhibit 10.1 Execution Version FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of March 31, 2023, is entered into by and among TG THERAPEUTICS, INC., a Delaware corporation (the “Parent”), TG BIOLOGICS, INC., a Delaware corporation (“TG Bio”; together with Parent and each of Pa
May 8, 2023	EX-10.4	Amended and Restated Warrant Agreement, dated March 31, 2023, by and between TG Therapeutics, Inc. and Hercules Private Credit Fund 1 L.P. Exhibit 10.4 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUN
May 8, 2023	EX-10.3	Amended and Restated Warrant Agreement, dated March 31, 2023, by and between TG Therapeutics, Inc. and Hercules Funding IV, LLC. Exhibit 10.3 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUN
May 1, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
May 1, 2023	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results First quarter 2023 BRIUMVI net sales of $7.8 million Over 400 BRIUMVI prescriptions in the first partial quarter from 165+ healthcare providers at 125+ centers Payor coverage in place for over 50% of covered lives for BRIUMVI Conference call to be held today, Monday, May 1, 2023, at 8:30 AM ET Ne
May 1, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitte
May 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2023 TG Therapeutics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2023 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Employer
April 21, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitte
April 3, 2023	SC 13G	TGTX / TG Therapeutics Inc / Darwin Global Management, Ltd. - TG THERAPEUTICS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TG Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 88322Q108 (CUSIP Number) March 22, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to wh
March 1, 2023	EX-21.1	Subsidiaries of TG Therapeutics, Inc. Exhibit 21.1 Subsidiaries of TG Therapeutics, Inc. Ariston Pharmaceuticals, Inc. TG Biologics, Inc. TG Therapeutics AUS Pty Ltd
March 1, 2023	10-K	ITEM 1B Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 1-32639 TG THER
February 28, 2023	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results Conference call to be held today, Tuesday, February 28, 2023, at 8:30 AM ET New York, NY, (February 28, 2023) – TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2022, and recent company developments. Michae
February 28, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2023 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Emp
February 9, 2023	SC 13G/A	TGTX / TG Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: TG Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 88322Q108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
December 28, 2022	EX-99.1	ULTIMATE I Exhibit 99.1 TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy) BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can be administered in a one-hour infusion twice-a-year following the starting dose U.S. Commercial launch expected Q1 2023 Company to host conference call on Thursday, December 29, 2022
December 28, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 28, 2022 TG Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 28, 2022 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Emp
November 10, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2022 TG Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2022 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Emp
November 10, 2022	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results Conference call to be held today, November 10, 2022 at 8:30 AM ET New York, NY, (November 10, 2022) – TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2022 and recent company developments, along with a business outlook for the re
November 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639
October 11, 2022	SC 13G/A	TGTX / TG Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: TG Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 88322Q108 Date of Event Which Requires Filing of this Statement: September 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
September 2, 2022	S-3ASR	As filed with the Securities and Exchange Commission on September 2, 2022 S-3ASR 1 tmb-20220902xs3asr.htm S-3ASR Table of Contents As filed with the Securities and Exchange Commission on September 2, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TG THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 36-3898269 (State or Oth
September 2, 2022	EX-4.3	Form of Indenture† Exhibit 4.3 ? TG THERAPEUTICS, INC. FORM OF INDENTURE Dated as of [ ], 20[ ] ? DEBT SECURITIES ? [ ] Trustee ? ? CROSS REFERENCE SHEET Cross-reference sheet of provisions of the Trust Indenture Act of 1939 and this indenture* ? ? ? ? ? Trust Indenture Act Section Indenture Section ?310 (a) ? 11.04(a), 16.02 ? (b) ? 11.01(f), 11.04(b), 11.05(1), 16.02 ? (b)(1) ? 11.04(b), 16.02 ?311 ? ? 11.01(f), 1
September 2, 2022	EX-FILING FEES	Filing Fee Table† Exhibit 107 Calculation of Filing Fee Table Form S-3ASR (Form Type) TG Therapeutics, Inc.
August 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 8, 2022	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results Conference call to be held today, August 8, 2022 at 8:30 AM ET New York, NY, (August 8, 2022) ? TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2022 and recent company developments, along with a business outlook for the remainder o
August 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2022 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (
June 24, 2022	S-8	As filed with the Securities and Exchange Commission on June 24, 2022 As filed with the Securities and Exchange Commission on June 24, 2022 File No. 333- ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TG Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? Delaware 36-3898269 (State or other jurisdiction of incorporation or organization) (I.R.S. Emp
June 24, 2022	EX-FILING FEES	Filing Fee Table. EXHIBIT 107 ? Calculation of Filing Fee Tables ? S-8 (Form Type) ? TG Therapeutics, Inc.
June 23, 2022	EX-10.1	TG Therapeutics, Inc. 2022 Incentive Plan. Exhibit 10.1 ? TG THERAPEUTICS, INC. 2022 INCENTIVE PLAN ARTICLE 1 PURPOSE 1.1.GENERAL. The purpose of the TG Therapeutics, Inc. 2022 Incentive Plan (the ?Plan?) is to promote the success, and enhance the value, of TG Therapeutics, Inc. (the ?Company?), by linking the personal interests of employees, officers, directors and consultants of the Company or any Affiliate (as defined below) to those of
June 23, 2022	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2022 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (I
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 29, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A INFORMATION ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant x ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permit
April 29, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __) DEF 14A 1 tmb-20220616xdef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, F
April 18, 2022	EX-99.1	TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL Exhibit 99.1 ? TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL Company voluntarily withdraws UKONIQ? from sale for approved indications of relapsed/refractory MZL and FL Company to host conference call, Monday, April 18, 2022 at 8:30 AM ET ? NEW YORK, April 15, 2022 (GLOBE NEWSWIRE) - TG Therapeutics, Inc. (NASDAQ: TGTX), today announced tha
April 18, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 15, 2022 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Employ
March 1, 2022	EX-10.31	WARRANT AGREEMENT To Purchase Shares of the Common Stock of TG THERAPEUTICS, INC. Dated as of December 30, 2021 (the “Effective Date”) ? Exhibit 10.31 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY C
March 1, 2022	EX-10.30	WARRANT AGREEMENT To Purchase Shares of the Common Stock of TG THERAPEUTICS, INC. Dated as of December 30, 2021 (the “Effective Date”) ? Exhibit 10.30 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY C
March 1, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2022 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS
March 1, 2022	EX-10.29	WARRANT AGREEMENT To Purchase Shares of the Common Stock of TG THERAPEUTICS, INC. Dated as of December 30, 2021 (the “Effective Date”) Exhibit 10.29 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COU
March 1, 2022	EX-21.1	Subsidiaries of TG Therapeutics, Inc. Exhibit 21.1 Subsidiaries of TG Therapeutics, Inc. ? ? Ariston Pharmaceuticals, Inc. ? ? ? TG Biologics, Inc. ? ? ? TG Therapeutics AUS Pty Ltd ? ?
March 1, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021. ☐ TRANSITION REPORT PURSUANT TO SECT Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 1, 2022	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET New York, NY, (March 1, 2022) ? TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2021, and recent company developments, along with a b
March 1, 2022	EX-10.28	AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT Certain identified information has been excluded from the document because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
February 10, 2022	SC 13G/A	TGTX / TG Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: TG Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 88322Q108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
January 27, 2022	8-K	Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 27, 2022 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IR
January 4, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 30, 2021 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (I
November 30, 2021	EX-99.1	TG Therapeutics Provides Regulatory Update Exhibit 99.1 ? TG Therapeutics Provides Regulatory Update ? Company to host conference call today, Tuesday, November 30, 2021 at 8:30 AM ET ? NEW YORK, November 30, 2021 (GLOBE NEWSWIRE) - TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the U.S. Food and Drug Administration (FDA) has notified the Company that it plans to host a meeting of the Oncologic Drugs Advisory Committee (ODAC) in conn
November 30, 2021	8-K	Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 30, 2021 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Numb
November 8, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2021 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Numbe
November 4, 2021	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results Conference call to be held today, Thursday, November 4, 2021 at 8:30 AM ET New York, NY, (November 4, 2021) ? TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2021 and recent company developments, along with a business outlook fo
August 6, 2021	EX-10.1	Amended and Restated Employment Agreement by and between TG Therapeutics, Inc. and Michael S. Weiss, dated June 18, 2021. Exhibit 10.1 ? AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this ?Agreement?), effective as of June 18th, 2021 (the ?Effective Date?), by and between TG Therapeutics, Inc., a Delaware corporation with an address at 2 Gansevoort Street, 9th Floor, New York, NY 10014 (the ?Company?), and MICHAEL S. WEISS, having a mailing address at (the ?Executive?). W I
August 6, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 2, 2021	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results Conference call to be held today, Monday, August 2, 2021 at 8:30 AM ET New York, NY, (August 2, 2021) ? TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ending June 30, 2021 and recent company developments, along with a business outlook for the re
August 2, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2021 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number)
June 23, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2021 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number)
June 21, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2021 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number)
June 21, 2021	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation of TG Therapeutics, Inc. dated June 16, 2021 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 23, 2021).* Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TG THERAPEUTICS, INC. TG Therapeutics, Inc., a corporation organized and existing under and by virtue of the Delaware General Corporation Law (the ?Corporation?), does hereby certify: FIRST: That on April 20, 2021, the Board of Directors of the Corporation adopted resolutions setting forth a proposed amend
May 10, 2021	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results Conference call to be held today, Monday, May 10, 2021 at 8:30 AM ET New York, NY, (May 10, 2021) ? TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first quarter ending March 31, 2021 and recent company developments, along with a business outlook for 2021. Micha
May 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2021 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (
May 10, 2021	10-Q	Quarterly Report - 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 30, 2021	DEFA14A	- DEFA14A ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? SCHEDULE 14A INFORMATION ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by
April 30, 2021	DEF 14A	- DEF 14A Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
April 20, 2021	PRE 14A	- PRE 14A Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
April 16, 2021	8-K	Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 16, 2021 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number)
April 16, 2021	EX-99.1	TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73 Exhibit 99.1 TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd Annual Meeting Ublituximab demonstrated superiority versus teriflunomide in reducing annualized relapse rates and MRI brain lesions Ublituximab was generally well tolerated, with no unexpected safety signals BLA s
April 13, 2021	EX-16.1	April 12, 2021 Exhibit 16.1 April 12, 2021 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred April 12, 2021, to be filed by our former client, TG Therapeutics, Inc. We agree with the statements made in response to that Item insofar as they relate to our Firm. Very truly yours, /s/ Coh
April 13, 2021	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 12, 2021 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number)
March 2, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 2, 2021 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number)
March 2, 2021	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2020 Financial Results Conference call to be held today, Tuesday, March 2, 2021 at 8:30 AM ET New York, NY, (March 2, 2021) – TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2020 and recent company developments, along with a bus
March 1, 2021	EX-4.5	Exhibit 4.2 ? Exhibit 4.5 DESCRIPTION OF SECURITIES ? When used herein, the terms ?we,? ?our,? and ?us? refer to TG Therapeutics, Inc. ? DESCRIPTION OF CAPITAL STOCK ? The following summary of the terms of our common stock may not be complete and is subject to, and qualified in its entirety by reference to, the terms and provisions of our amended and restated certificate of incorporation and our restated byla
March 1, 2021	EX-21.1	Subsidiaries of TG Therapeutics, Inc. Exhibit 21.1 Subsidiaries of TG Therapeutics, Inc. ? ? Ariston Pharmaceuticals, Inc. ? ? ? TG Biologics, Inc. ? ? ? TG Therapeutics AUS Pty Ltd ? ?
March 1, 2021	10-K	Annual Report - 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A (Amendment No. 1)* Under the Securities Exchange Act of 1934 TG Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A (Amendment No. 1)* Under the Securities Exchange Act of 1934 TG Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 88322Q108 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs
February 10, 2021	SC 13G	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: TG Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 88322Q108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Ru
February 10, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* TG THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Secur UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* TG THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 88322Q108 (CUSIP Number) January 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru
February 10, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* TG THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Secur UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* TG THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 88322Q108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r
February 8, 2021	EX-99.1	UKONIQ MZL (n=69) Exhibit 99.1 TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib) UKONIQ is approved for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen UKONIQ is approved for adult patients with relapsed or refractory follicular lymphoma after at least three prior lines of systemic therapy UKONIQ is the first and only inhibi
February 8, 2021	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 5, 2021 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Empl
December 16, 2020	424B5	CALCULATION OF REGISTRATION FEE 424B5 1 tm2038389-2424b5.htm 424B5 TABLE OF CONTENTS CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Maximum Offering Price Per Unit Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, par value $0.001 per share 7,268,000 $ 43.50 $ 316,158,000 $ 34,492.84 (1) Calculated in accordance with Rule 457(r) under the Secu
December 16, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2020 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction of Incorporation) (Commission Fil
December 16, 2020	EX-1.1	Underwriting Agreement, dated December 14, 2020, by and among TG Therapeutics, Inc. and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein. Exhibit 1.1 EXECUTION VERSION TG THERAPEUTICS, INC. 6,320,000 Shares of Common Stock Underwriting Agreement December 14, 2020 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 Cantor Fitzgerald & Co. 499 Park Avenue New York, New York 10022 As Rep
December 14, 2020	424B5	Joint Book-Running Managers TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.
December 10, 2020	EX-99.1	TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis Exhibit 99.1 TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis Both studies met their primary endpoint of significantly reducing annualized relapse rate (ARR) (p<0.005 in each study) with ublituximab demonstrating an ARR of <0.10 in each of the studies Relative reducti
December 10, 2020	8-K	Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 10, 2020 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Numb
December 8, 2020	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 7, 2020 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Empl
December 8, 2020	EX-99.2	TG Therapeutics Announces Pivotal Data from the UNITY-CLL and UNITY-NHL Clinical Trials Presented at the 62nd American Society of Hematology Annual Meeting Exhibit 99.2 TG Therapeutics Announces Pivotal Data from the UNITY-CLL and UNITY-NHL Clinical Trials Presented at the 62nd American Society of Hematology Annual Meeting UNITY-CLL: U2 significantly improved progression-free survival over obinutuzumab plus chlorambucil (HR=0.54, p<0.0001) as well as ORR (p<0.001) in patients with CLL; with consistent PFS improvement across treatment naïve CLL (HR=0.
December 8, 2020	EX-99.1	TG Therapeutics Announces Triple Combination Data Presentations at the at the 62nd American Society of Hematology Annual Meeting Exhibit 99.1 TG Therapeutics Announces Triple Combination Data Presentations at the at the 62nd American Society of Hematology Annual Meeting U2 + Venetoclax: 100% ORR at cycle 12 (n=27), including 41% CR rate, and 96% of patients achieving undetectable MRD in the peripheral blood and 77% achieving undetectable MRD in bone marrow U2 + TG-1701 (BTKi): Dose escalation cohort (n=14) resulted in 79% O
November 9, 2020	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2020 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Empl
November 9, 2020	424B5	CALCULATION OF REGISTRATION FEE Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-233636 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, par value $0.001 per share $400,000,000 $43,640 (1)The registration fee related to shares of common stock having an aggregate offering price of $400,000
November 9, 2020	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results New York, NY, (November 9, 2020)– TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2020 and recent company developments. Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, stated, “This has been a ver
November 9, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2020 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Empl
November 9, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639
November 5, 2020	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2020 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Empl
November 5, 2020	EX-99.1	TG Therapeutics Highlights Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting Exhibit 99.1 TG Therapeutics Highlights Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting UNITY-CLL: U2 significantly improved progression-free survival over obinutuzimab plus chlorambucil (HR=0.54, p<0.0001) as well as ORR (p<0.001) in patients with CLL; with consistent PFS improvement across treatment naïve CLL (HR=0.48) and relapsed/refractory CLL (H
August 10, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2020 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction of Incorporation) (Commission File
August 10, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG T
August 10, 2020	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results New York, NY, (August 10, 2020)– TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2020 and recent company developments. Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, stated, “We are extremely please
June 24, 2020	EX-10.1	Amendment to TG Therapeutics, Inc. Amended and Restated 2012 Incentive Plan. Exhibit 10.1 AMENDMENT TO THE TG THERAPEUTICS, INC. AMENDED AND RESTATED 2012 INCENTIVE PLAN This Amendment to the TG Therapeutics, Inc. Amended and Restated 2012 Incentive Plan (the “Plan”), is hereby adopted, effective as of the date indicated below. W I T N E S E T H: WHEREAS, TG Therapeutics, Inc. (the “Company”) maintains the Plan, and the Plan is currently in effect; and WHEREAS, Section 16.
June 24, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2020 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Employe
June 10, 2020	SC 13G/A	TGTX / TG Therapeutics, Inc. / RA Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* TG THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 88322Q108 (CUSIP Number) May 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p
May 29, 2020	PX14A6G	- PX14A6G Name of Registrant: TG Therapeutics, Inc. Name of persons relying on exemption: California Public Employees Retirement System (CalPERS) Address of persons relying on exemption: 400 Q Street, Sacramento, CA 95811 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. Submission is not required of this filer under the terms of the Rule, bu
May 18, 2020	424B5	CALCULATION OF REGISTRATION FEE CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Maximum Offering Price Per Unit Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, par value $0.
May 18, 2020	EX-1.1	Underwriting Agreement, dated May 14, 2020, by and among TG Therapeutics, Inc. and J.P. Morgan Securities LLC, Jefferies LLC, Evercore Group L.L.C. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein. Exhibit 1.1 TG THERAPEUTICS, INC. 8,500,000 Shares of Common Stock Underwriting Agreement May 14, 2020 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Jefferies LLC 520 Madison Avenue New York, New York 10022 Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 Cantor Fitzgerald & Co. 499 Park Avenue New York, New York 10022 As Representatives of the several Un
May 18, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2020 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Employer
May 14, 2020	424B5	Subject to completion, dated May 14, 2020 The information in this preliminary prospectus supplement is not complete and may be changed.
May 11, 2020	EX-99.1	TG Therapeutics, Inc. Selected Condensed Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results New York, NY, (May 11, 2020)– TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first quarter ended March 31, 2020 and recent company developments. Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, stated, “The first few months of 202
May 11, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG
May 11, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2020 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Employer
May 5, 2020	EX-99.1	TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia Exhibit 99.1 TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia UNITY-CLL trial met the primary endpoint of improved progression-free survival (PFS) (p<.0001) and will be stopped early for superior efficacy observed at the interim analysis P
May 5, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2020 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Employer
April 30, 2020	EX-99.1	TG Therapeutics Bolsters Board of Directors with the Appointment of Sagar Lonial, MD Exhibit 99.1 TG Therapeutics Bolsters Board of Directors with the Appointment of Sagar Lonial, MD New York, NY, (April 29, 2020) TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the appointment of Sagar Lonial, MD, FACP, to the Company’s Board of Directors. Dr. Lonial has extensive experience in multiple myeloma and lymphoma treatment and research, and most recently has focused on developing
April 30, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 24, 2020 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Employ
April 29, 2020	DEF 14A	Proxy Statement on Schedule 14A filed with the SEC on April 29, 2020 Table of Contents c UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
April 29, 2020	DEFA14A	- DEFA14A DEFA14A 1 tgtx-20200429xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Co
March 20, 2020	424B5	CALCULATION OF REGISTRATION FEE Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-233636 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, par value $0.001 per share $200,000,000 $25,960 (1)The registration fee related to shares of common stock having an aggregate offering price of $200,000
March 20, 2020	EX-1.1	At Market Issuance Sales Agreement, among the Company and Jefferies LLC, Cantor Fitzgerald & Co. and B. Riley FBR, Inc., dated March 20, 2020. Exhibit 1.1 TG THERAPEUTICS, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement March 20, 2020 Jefferies LLC 520 Madison Ave, 10th Floor New York, NY 10022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 B. Riley FBR, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: TG Therapeutics, Inc. (the “Company”), confirms its agreement (thi
March 20, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 20, 2020 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Employ
March 3, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2020 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-32639 36-3898269 (State or Other Jurisdiction (Commission File Number) (IRS Employe
March 3, 2020	EX-99.1	TG Therapeutics, Inc. Selected Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2019 Financial Results Conference call to be held today, Tuesday, March 3, 2020 at 8:00 AM ET New York, NY, (March 3, 2020) – TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2019 and recent company developments, along with a bus
March 2, 2020	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 1-32639 TG THER
March 2, 2020	EX-4.5	DESCRIPTION OF SECURITIES Exhibit 4.5 DESCRIPTION OF SECURITIES When used herein, the terms “we,” “our,” and “us” refer to TG Therapeutics, Inc. DESCRIPTION OF CAPITAL STOCK The following summary of the terms of our common stock may not be complete and is subject to, and qualified in its entirety by reference to, the terms and provisions of our amended and restated certificate of incorporation and our restated bylaws. You
March 2, 2020	EX-21.1	Subsidiaries of TG Therapeutics, Inc. Exhibit 21.1 Subsidiaries of TG Therapeutics, Inc. Ariston Pharmaceuticals, Inc. TG Biologics, Inc. TG Therapeutics AUS Pty Ltd
February 14, 2020	SC 13G/A	TGTX / TG Therapeutics, Inc. / venBio Select Advisor LLC - TG THERAPEUTICS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* TG Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 88322Q108 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant
February 14, 2020	SC 13G/A	TGTX / TG Therapeutics, Inc. / RA Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TG THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 88322Q108 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r
February 14, 2020	SC 13G/A	TGTX / TG Therapeutics, Inc. / BRIDGER MANAGEMENT, LLC - SCHEDULE 13G HOLDINGS REPORT AMENDMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
January 24, 2020	SC 13G/A	TGTX / TG Therapeutics, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) TG THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 88322Q108 (CUSIP Number) DECEMBER 31, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the ru
January 2, 2020	SC 13G	TGTX / TG Therapeutics, Inc. / GREAT POINT PARTNERS LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Amendment No )* Under the Securities Exchange Act of 1934 TG Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 88322Q108 (CUSIP Number) December 23, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
December 26, 2019	EX-99.1	FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 99.1 FORM OF SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of the 22nd day of December, 2019, by and among TG Therapeutics, Inc., a Delaware corporation (the “Company”) and the purchasers executing the purchaser signature page attached hereto (each a “Purchaser”); and WHEREAS, the Company has prepared and filed with the Secu
December 26, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 22, 2019 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number) 3
December 23, 2019	424B5	Calculation of Registration Fee Amount to be Registered Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee (1) Common Stock, par value $0.001 per share 5,434,783 $9.20 $50,000,000 $6,490 Filed Pursuant to Rule 424(b)(5) Registration No. 333-233636 Calculation of Registration Fee Amount to be Registered Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee (1) Common Stock, par value $0.001 per share 5,434,783 $9.20 $50,000,000 $6,490 (1) Calculated in accordance with Rule 457 under the Securities Act of 1933, as amended. PRO
December 9, 2019	EX-99.2	TG Therapeutics Announces Phase I Data Presentation for TG-1701, a Once-Daily BTK Inhibitor, as a Single Agent and in Triple Combination with Ublituximab and Umbralisib (U2), at the 61 Exhibit 99.2 TG Therapeutics Announces Phase I Data Presentation for TG-1701, a Once-Daily BTK Inhibitor, as a Single Agent and in Triple Combination with Ublituximab and Umbralisib (U2), at the 61st American Society of Hematology Annual Meeting and Exposition Proprietary triplet of U2 plus TG-1701 (BTK inhibitor) induced 86% ORR (6 of 7) in patients with relapsed/refractory NHL and CLL at the low
December 9, 2019	EX-99.1	TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61 Exhibit 99.1 TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition 100% overall response rate (ORR) in relapsed/refractory CLL patients treated with U2 (umbralisib + ublituximab) plus venetoclax at cycle 7 (n=13) 100% of patients (n=
December 9, 2019	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 8, 2019 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number) 36
November 12, 2019	EX-99.1	TG Therapeutics, Inc. Selected Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results Conference call to be held today, Tuesday, November 12, 2019 at 8:30 AM ET New York, NY, (November 12, 2019) – TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2019 and recent company developments. Michael S. Weiss, the Company's
November 12, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2019 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number) 3
November 12, 2019	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30929 TG THERAPEUTICS,
October 28, 2019	EX-99.1	TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma Exhibit 99.1 TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma Follicular lymphoma cohort met the primary endpoint of overall response rate (ORR) Umbralisib monotherapy appeared to be well tolerated with a safety profile consistent with previous reports TG plans to present
October 28, 2019	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 28, 2019 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number) 36
September 12, 2019	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 12, 2019 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number)
September 12, 2019	EX-99.1	TG Therapeutics Presents Data for Ublituximab at the 35 Exhibit 99.1 TG Therapeutics Presents Data for Ublituximab at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) New York, NY, (September 12, 2019) TG Therapeutics, Inc. (NASDAQ: TGTX), today presented the first look at the ULTIMATE I & II Phase 3 trial design and demographic data and updated Phase 2 extension trial data for ublituximab, t
September 5, 2019	S-3ASR	TGTX / TG Therapeutics, Inc. S-3ASR - - FORM S-3ASR As filed with the Securities and Exchange Commission on September 5, 2019 Registration No.
September 5, 2019	EX-4	TG THERAPEUTICS, INC. FORM OF Dated as of [ ], 20[ ] DEBT SECURITIES CROSS REFERENCE SHEET Exhibit 4.1 TG THERAPEUTICS, INC. FORM OF INDENTURE Dated as of [ ], 20[ ] DEBT SECURITIES [] Trustee CROSS REFERENCE SHEET Cross-reference sheet of provisions of the Trust Indenture Act of 1939 and this indenture* Trust Indenture Act Section Indenture Section §310 (a) 11.04(a), 16.02 (b) 11.01(f), 11.04(b), 11.05(1), 16.02 (b)(1) 11.04(b), 16.02 §311 11.01(f), 16.02 §312 14.02(d), 16.02 (b) 11.10
September 5, 2019	RW	TGTX / TG Therapeutics, Inc. RW - - FORM RW RW 1 tgtxformrw.htm FORM RW TG THERAPEUTICS, INC. 52 Gansevoort Street, 9th Floor New York, New York 10014 September 5, 2019 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: TG Therapeutics, Inc. (CIK 0001001316) Application for Withdrawal of Registration Statement on Form S-3 filed on August 30, 2019 (File No. 333-2335
August 30, 2019	EX-4	TG THERAPEUTICS, INC. FORM OF Dated as of [ ], 20[ ] DEBT SECURITIES CROSS REFERENCE SHEET EX-4 2 tgtxex41.htm EXHIBIT 4.1 Exhibit 4.1 TG THERAPEUTICS, INC. FORM OF INDENTURE Dated as of [ ], 20[ ] DEBT SECURITIES [] Trustee CROSS REFERENCE SHEET Cross-reference sheet of provisions of the Trust Indenture Act of 1939 and this indenture* Trust Indenture Act Section Indenture Section §310 (a) 11.04(a), 16.02 (b) 11.01(f), 11.04(b), 11.05(1), 16.02 (b)(1) 11.04(b), 16.02 §311 11.01(f), 16.0
August 30, 2019	S-3	TGTX / TG Therapeutics, Inc. S-3 - - S-3 S-3 1 tgtxs3.htm S-3 As filed with the Securities and Exchange Commission on August 30, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TG THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 36-3898269 (State or Other Jurisdiction of Incorporation or Or
August 9, 2019	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2019 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number) 36-3
August 9, 2019	EX-7	TG Therapeutics, Inc. Selected Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results Conference call to be held today, Friday, August 9, 2019 at 8:30 AM ET New York, NY, (August 9, 2019) – TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2019 and recent company developments. Michael S. Weiss, the Company's Executive
August 9, 2019	EX-10.2	MASTER SERVICES AGREEMENT SAMSUNG BIOLOGICS CO., LTD. TG THERAPEUTICS, INC. Exhibit 10.2 Execution Version MASTER SERVICES AGREEMENT between SAMSUNG BIOLOGICS CO., LTD. and TG THERAPEUTICS, INC. 1 Table of Contents SECTION 1 DEFINITIONS 3 SECTION 2 RELATED AGREEMENTS AND EXHIBITS 8 SECTION 3 MANAGEMENT OF SERVICE 9 SECTION 4 SERVICES 10 SECTION 5 SERVICE DESCRIPTIONS 12 SECTION 6 CHANGES TO THE SPECIFICATIONS, ANALYTICAL METHODS, MANUFACTURING PROCESS, FACILITY OR EQUIPME
August 9, 2019	EX-10.1	AMENDED AND RESTATED COLLABORATION AGREEMENT Exhibit 10.1 Certain identified information has been excluded from the document because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDED AND RESTATED COLLABORATION AGREEMENT THIS AMENDED AND RESTATED COLLABORATION AGREEMENT (the “Agreement”) is dated as of June 19, 2019 by and between Checkpoint Therapeutics, Inc., a Delaware corporation organized
August 9, 2019	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30929 TG THERAPEUTICS, INC.
June 13, 2019	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2019 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number) 36-38
May 31, 2019	PX14A6G	TGTX / TG Therapeutics, Inc. PX14A6G - - PX14A6G Name of Registrant: TG Therapeutics, Inc. Name of persons relying on exemption: California Public Employees Retirement System (CalPERS) Address of persons relying on exemption: 400 Q Street, Sacramento, CA 95811 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. Submission is not required of this filer under the terms of the Rule, bu
May 10, 2019	EX-99	TG Therapeutics, Inc. Selected Consolidated Financial Data Exhibit 99.1 TG Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results Conference Call to be held today, Friday, May 10, 2019 at 8:00 AM ET New York, NY, (May 10, 2019) – TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first quarter ended March 31, 2019 and recent company developments. Michael S. Weiss, the Company's Executive Chai
May 10, 2019	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2019 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number) 36-389
May 10, 2019	10-Q	Quarterly Report - 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30929 TG THERAPEUTICS, INC.
May 7, 2019	EX-99	TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71 Exhibit 99.1 TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Meeting Ublituximab treatment continues to be well tolerated with a median duration of follow-up of 97.5 weeks New York, NY, (May 7, 2019) TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicate
May 7, 2019	8-K	Financial Statements and Exhibits, Other Events 8-K 1 v0507198k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2019 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commiss
April 30, 2019	DEFA14A	TGTX / TG Therapeutics, Inc. DEFA14A DEFA14A DEFA14A 1 finalregisterednoticecard.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of th
April 30, 2019	DEF 14A	April 30, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)
April 1, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 1, 2019 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number) 36-38
April 1, 2019	EX-99.1	Interim Efficacy Population (n=42) Exhibit 99.1 TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting Overall response rate (ORR) of 52% (N=42), with complete response (CR) rate of 19%, by central independent review committee (IRC) Responses were durable, with median duration of response (DOR) not reached
March 11, 2019	SC 13G	TGTX / TG Therapeutics, Inc. / BRIDGER MANAGEMENT, LLC - SCHEDULE 13G HOLDINGS REPORT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
March 7, 2019	SC 13G	TGTX / TG Therapeutics, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 TG THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 88322Q108 (CUSIP Number) MARCH 1, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which t
March 5, 2019	424B5	4,100,000 Shares Common Stock PROSPECTUS SUPPLEMENT (to Prospectus dated June 13, 2017) 4,100,000 Shares Common Stock We are offering 4,100,000 shares of our common stock, $0.
March 5, 2019	EX-10.2	LOAN AND SECURITY AGREEMENT Exhibit 10.2 Execution Version LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of February 28, 2019 and is entered into by and among TG THERAPEUTICS, INC., a Delaware corporation (the “Parent”), TG BIOLOGICS, INC., a Delaware corporation (“TG Bio”; together with Parent and each of Parent’s Subsidiaries that delivers a Joinder Agreement pursuant to Section 7.13 of
March 5, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2019 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number) 3
March 5, 2019	EX-10.4	WARRANT AGREEMENT To Purchase Shares of the Common Stock of TG THERAPEUTICS, INC. Dated as of February 28, 2019 (the “Effective Date”) Exhibit 10.4 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUN
March 5, 2019	EX-10.1	TG THERAPEUTICS, INC. 4,100,000 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement Execution Version TG THERAPEUTICS, INC. 4,100,000 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement March 1, 2019 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: TG Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Cantor Fitzgerald & Co. (“Cantor” or the “Underwriter”) an aggregate of 4,100,000 share
March 5, 2019	EX-10.3	WARRANT AGREEMENT To Purchase Shares of the Common Stock of TG THERAPEUTICS, INC. Dated as of February 28, 2019 (the “Effective Date”) Exhibit 10.3 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUN
March 1, 2019	10-K	December 31, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 1-32639 TG THERAPEUTICS, INC. (Ex
March 1, 2019	EX-10.22	MASTER SERVICES AGREEMENT TG THERAPEUTICS, INC. MASTER SERVICES AGREEMENT Exhibit 10.22 CONFIDENTIAL TREATMENT REQUESTED. Confidential portions of this document have been redacted and have been separately filed with the Commission. MASTER SERVICES AGREEMENT between * and TG THERAPEUTICS, INC. Table of Contents SECTION 1 DEFINITIONS 3 SECTION 2 RELATED AGREEMENTS AND EXHIBITS 10 SECTION 3 MANAGEMENT OF SERVICE 11 SECTION 4 SERVICES 14 SECTION 5 SERVICE DESCRIPTIONS 16 SE
March 1, 2019	EX-21.1	Subsidiaries of TG Therapeutics, Inc. Exhibit 21.1 Subsidiaries of TG Therapeutics, Inc. Ariston Pharmaceuticals, Inc. TG Biologics, Inc. TG Therapeutics AUS Pty Ltd
February 28, 2019	424B5	Subject to completion, dated February 28, 2019 The information in this prospectus is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to completion
February 28, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2019 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number) 3
February 28, 2019	EX-99.1	TG Therapeutics Announces Positive Outcome from UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib in Patients with Relapsed/Refractory Marginal Zone Lymphoma Exhibit 99.1 TG Therapeutics Announces Positive Outcome from UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib in Patients with Relapsed/Refractory Marginal Zone Lymphoma Study met the primary endpoint of Overall Response Rate (ORR) Interim data to be presented in an oral presentation at the 2019 American Association of Cancer Research (AACR) annual meeting on April 1, 2019 Umbralisib was pre
February 14, 2019	SC 13G	TGTX / TG Therapeutics, Inc. / venBio Select Advisor LLC - TG THERAPEUTICS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* TG Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 88322Q108 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to
February 14, 2019	SC 13G	TGTX / TG Therapeutics, Inc. / RA Capital Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TG THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 88322Q108 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru
February 14, 2019	SC 13G/A	TGTX / TG Therapeutics, Inc. / BRIDGER MANAGEMENT, LLC - SCHEDULE 13G HOLDINGS REPORT AMENDMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
January 22, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 22, 2019 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number) 36
January 22, 2019	EX-99.1	TG Therapeutics Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Umbralisib for the Treatment of Marginal Zone Lymphoma Exhibit 99.1 TG Therapeutics Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Umbralisib for the Treatment of Marginal Zone Lymphoma Breakthrough Therapy Designation granted based on interim data from the Marginal Zone Lymphoma cohort of the UNITY-NHL trial NEW YORK, NY (January 22, 2019) – TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company de
December 4, 2018	EX-99.2	TG Therapeutics, Inc. Exhibit 99.2 TG Therapeutics, Inc. Announces Follow-Up Data from the Triple Combination of Ublituximab, Umbralisib, and Bendamustine in Patients with DLBCL and FL at 60th American Society of Hematology Annual Meeting and Exposition NEW YORK, December 4, 2018 - TG Therapeutics, Inc. (NASDAQ: TGTX), today announced updated clinical data from its Phase I/Ib trial of ublituximab (TG-1101), the Company

DE:NKB2	€ ٢٦٫٩٨
GB:0VGI
IT:1TGTX	€ ٢٤٫٦٢

TGTX / TG Therapeutics, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

الإحصائيات الأساسية

SEC Filings

SEC Filings (Chronological Order)

Other Listings